$912.94K in average volume shows that Nurix Therapeutics Inc (NRIX) is heading in the right direction

On Tuesday, Nurix Therapeutics Inc (NASDAQ: NRIX) opened lower -4.26% from the last session, before settling in for the closing price of $12.69. Price fluctuations for NRIX have ranged from $8.18 to $29.56 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales drop of Healthcare Sector giant was -38.86%. Company’s average yearly earnings per share was noted 0.33% at the time writing. With a float of $74.92 million, this company’s outstanding shares have now reached $76.43 million.

Let’s determine the extent of company efficiency that accounts for 286 employees. In terms of profitability, gross margin is 40.79%, operating margin of -260.75%, and the pretax margin is -233.61%.

Nurix Therapeutics Inc (NRIX) Insider Activity

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nurix Therapeutics Inc is 2.00%, while institutional ownership is 110.33%. The most recent insider transaction that took place on May 02 ’25, was worth 70,243. In this transaction Chief Financial Officer of this company sold 6,198 shares at a rate of $11.33, taking the stock ownership to the 33,724 shares. Before that another transaction happened on May 02 ’25, when Company’s Officer proposed sale 6,198 for $11.16, making the entire transaction worth $69,170.

Nurix Therapeutics Inc (NRIX) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around 0.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.78% during the next five years compared to -38.86% drop over the previous five years of trading.

Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators

Check out the current performance indicators for Nurix Therapeutics Inc (NRIX). In the past quarter, the stock posted a quick ratio of 6.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.51.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -3.55 in one year’s time.

Technical Analysis of Nurix Therapeutics Inc (NRIX)

Looking closely at Nurix Therapeutics Inc (NASDAQ: NRIX), its last 5-days average volume was 1.78 million, which is a jump from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 32.82%.

During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 42.78%, which indicates a significant increase from 28.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.83 in the past 14 days, which was higher than the 0.78 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $11.28, while its 200-day Moving Average is $16.79. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $12.52. Second resistance stands at $12.88. The third major resistance level sits at $13.09. If the price goes on to break the first support level at $11.95, it is likely to go to the next support level at $11.74. Should the price break the second support level, the third support level stands at $11.38.

Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats

There are currently 76,449K shares outstanding in the company with a market cap of 928.86 million. Presently, the company’s annual sales total 54,550 K according to its annual income of -193,570 K. Last quarter, the company’s sales amounted to 44,060 K and its income totaled -43,460 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.